JP Morgan Chase
ACRV icon

JP Morgan Chase’s Acrivon Therapeutics ACRV Stock Holding History

JP Morgan Chase’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34K Buy
751
+113
+18% +$192 ﹤0.01% 7291
2026
Q1 		$823 Sell
638
-16,226
-96% -$28.3K ﹤0.01% 7144
2025
Q4 		$40.6K Buy
16,864
+15,123
+869% +$32.9K ﹤0.01% 6311
2025
Q3 		$3.15K Buy
1,741
+323
+23% +$454 ﹤0.01% 6841
2025
Q2 		$1.69K Sell
1,418
-7,061
-83% -$9.69K ﹤0.01% 6559
2025
Q1 		$17.2K Sell
8,479
-17,330
-67% -$93.3K ﹤0.01% 6193
2024
Q4 		$155K Sell
25,809
-8,182
-24% -$59.5K ﹤0.01% 5583
2024
Q3 		$238K Buy
33,991
+28,748
+548% +$227K ﹤0.01% 5327
2024
Q2 		$30.4K Buy
5,243
+284
+6% +$2.29K ﹤0.01% 6030
2024
Q1 		$35.5K Sell
4,959
-28,384
-85% -$132K ﹤0.01% 6062
2023
Q4 		$164K Buy
33,343
+6,771
+25% +$35.8K ﹤0.01% 5496
2023
Q3 		$254K Buy
26,572
+19,645
+284% +$227K ﹤0.01% 4918
2023
Q2 		$89.8K Buy
6,927
+297
+4% +$3.6K ﹤0.01% 5514
2023
Q1 		$84K Buy
+6,630
New +$111K ﹤0.01% 5501

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's ACRV Position: Q2 2026 in Review

JP Morgan Chase increased its Acrivon Therapeutics (ACRV) stake by 18% in Q2 2026, buying an estimated $192 and bringing the position to 751 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #7291.

JP Morgan Chase first reported a position in ACRV in Q1 2023 and has held it in 14 quarters since. The position peaked at $254K in Q3 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • JP Morgan Chase held 751 shares of Acrivon Therapeutics worth $1.34K as of Q2 2026.
  • JP Morgan Chase bought 113 Acrivon Therapeutics shares in Q2 2026, an estimated $192.
  • Acrivon Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7291 holding.
  • JP Morgan Chase first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • JP Morgan Chase's Acrivon Therapeutics position peaked at $254K in Q3 2023.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.